← board
PHAR
distress 0/10 · well-funded / low risk$12.96-1%today-39% from 52w high
Revenue
$72M
Liquidity
$178M
Runway
—
Shares 1y
0%
Price & events
-35.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
-3.3%
1W
+2.0%
1M
-24.1%
3M
-35.0%
6M
+32.2%
1Y
+49.8%
2Y
+16.0%
5Y
-13.1%
All
Overview
- Market Cap
- $9.09B
- Enterprise Value
- $9.13B
- Volume
- 2.10K
- 52 Week Range
- $9.80 – $21.18
- Total Shares
- 701.68M
- Float Shares
- 73.29M
- Short %
- 0.00%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 0.14%
- RVOL
- 0.36x
- Beta
- 0.09
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $34 (+165% upside) · 4 analysts
- 2026-04-10Canaccord GenuityBuy
- 2026-03-24HC Wainwright & Co.Buy
- 2026-03-13OppenheimerOutperform
- 2025-03-21HC Wainwright & Co.Buy
- 2025-03-20HC Wainwright & Co.Buy
- 2025-03-14HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.